Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets boosted its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 51.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 293,587 shares of the medical device company's stock after acquiring an additional 99,890 shares during the quarter. BNP Paribas Financial Markets owned about 0.45% of Tandem Diabetes Care worth $12,451,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Oppenheimer & Co. Inc. grew its position in Tandem Diabetes Care by 368.5% during the third quarter. Oppenheimer & Co. Inc. now owns 26,125 shares of the medical device company's stock worth $1,108,000 after buying an additional 20,549 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Tandem Diabetes Care by 32.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 272,097 shares of the medical device company's stock worth $11,540,000 after acquiring an additional 66,687 shares in the last quarter. LMR Partners LLP grew its holdings in shares of Tandem Diabetes Care by 235.5% in the 3rd quarter. LMR Partners LLP now owns 33,824 shares of the medical device company's stock worth $1,434,000 after acquiring an additional 23,743 shares during the period. abrdn plc purchased a new position in Tandem Diabetes Care in the 3rd quarter valued at approximately $6,126,000. Finally, The Manufacturers Life Insurance Company raised its holdings in Tandem Diabetes Care by 310.2% during the second quarter. The Manufacturers Life Insurance Company now owns 35,980 shares of the medical device company's stock worth $1,450,000 after purchasing an additional 27,208 shares during the last quarter.

Analysts Set New Price Targets

TNDM has been the topic of several research reports. Robert W. Baird lowered their target price on Tandem Diabetes Care from $39.00 to $37.00 and set a "neutral" rating on the stock in a report on Thursday, November 7th. Canaccord Genuity Group assumed coverage on shares of Tandem Diabetes Care in a report on Thursday, August 8th. They set a "buy" rating and a $57.00 target price for the company. Barclays lifted their target price on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an "overweight" rating in a research report on Friday, November 8th. Morgan Stanley upgraded shares of Tandem Diabetes Care from an "equal weight" rating to an "overweight" rating and set a $45.00 price target on the stock in a research report on Monday. Finally, Sanford C. Bernstein started coverage on Tandem Diabetes Care in a research report on Wednesday, November 6th. They set an "outperform" rating and a $42.00 price objective for the company. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat, Tandem Diabetes Care currently has an average rating of "Moderate Buy" and an average price target of $54.25.

Insider Buying and Selling at Tandem Diabetes Care

In related news, Director Kim D. Blickenstaff sold 10,000 shares of the business's stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $30.00, for a total value of $300,000.00. Following the transaction, the director now owns 195,190 shares in the company, valued at approximately $5,855,700. The trade was a 4.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.20% of the stock is currently owned by corporate insiders.

Tandem Diabetes Care Trading Up 6.1 %

NASDAQ:TNDM traded up $1.88 during mid-day trading on Monday, reaching $32.51. The company's stock had a trading volume of 1,589,399 shares, compared to its average volume of 1,593,246. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. The stock has a market cap of $2.14 billion, a P/E ratio of -16.74 and a beta of 1.36. The company's fifty day simple moving average is $34.88 and its two-hundred day simple moving average is $40.74. Tandem Diabetes Care, Inc. has a twelve month low of $20.52 and a twelve month high of $53.69.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its earnings results on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.08. The business had revenue of $243.97 million for the quarter, compared to analyst estimates of $224.14 million. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The business's quarterly revenue was up 31.4% on a year-over-year basis. During the same period last year, the company posted ($0.38) EPS. On average, equities analysts predict that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current year.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.